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There is substantial evidence for a role in cancer of the bioactive lipid sphingosine 1-
phosphate (S1P), the enzyme sphingosine kinase 1 (that catalyses S1P formation) and
S1P-speciﬁc G protein-coupled receptors. This perspective highlights recent ﬁndings
demonstrating that sphingosine kinase 1 and S1P receptors are new important biomark-
ers for detection of early cancer and progression to aggressive cancer. The impact of the
sub-cellular distribution of S1P metabolizing enzymes and S1P receptors and their spatial
functional interaction with oncogenes is considered with respect to prognostic outcome.
These ﬁndings suggest that S1P, in addition to being a biomarker of clinical prognosis, might
also be a new therapeutic target for intervention in cancer.
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INTRODUCTION
Effective cancer therapy remains an important medical chal-
lenge. Genetic instability that leads to constitutive activating
mutations of oncogenes and inactivating mutations of tumor
suppressors leads to the hallmarks of cancer (Hanahan and Wein-
berg, 2011). It is important to identify new biomarkers that
report early stage cancer or early transformation to aggressive
cancer and ideally from clinical specimens. This might there-
fore enable early detection of cancer and inform on appropriate
personalized chemotherapeutic intervention, thereby affording
opportunities for improved therapies. It also follows that these
biomarkers can be used to enable monitoring of effective drug
intervention speciﬁc to a personalized clinical approach. Sphin-
gosine 1-phosphate (S1P) is a bioactive lipid that has emerged as
having an important role in both solid tumors and hematologi-
cal cancer (Pyne and Pyne, 2010). There is now evidence that the
enzymes involved in the metabolism of S1P and the cellular targets
of this signaling lipid are important new therapeutically relevant
biomarkers of clinical prognosis. Indeed, S1P promotes neo-
plastic transformation, enhances cell survival/reduces apoptosis,
induces chemotherapeutic resistance, reduces senescence, pro-
motes angiogenesis and creation of a tumor microenvironment,
increases invasiveness/metastasis, and is involved in inﬂammation
(Pyne and Pyne, 2010).
SPHINGOSINE 1-PHOSPHATE METABOLISM
AND ACTION IN CANCER
Sphingosine is formed from breakdown of complex sphingolipids
and is further metabolized to S1P by the enzyme, sphingosine
kinase. There are two isoforms of sphingosine kinase (SK1 and
SK2) that are encoded by distinct genes and differ in their bio-
chemical properties, sub-cellular localization and functions (Pyne
and Pyne, 2010). S1P can be irreversibly degraded by S1P lyase,
which represents the only exit point in the sphingolipid metabolic
pathway. Alternatively, S1P can be recycled to sphingosine by the
action of lipid phosphate- and S1P-speciﬁc phosphatases. S1P is a
bioactive lipid that binds to ﬁve different G protein-coupled S1P
receptors (termed S1P1−5) to induce cellular responses. Intra-
cellular S1P directly binds to TRAF2 to regulate RIP1/NFκB
signaling (Alvarez et al., 2010), to prohibitin 2 to affect mitochon-
drial oxidative phosphorylation (Strub et al., 2011), and to β-site
APP cleaving enzyme-1 to increase amyloid-β peptide produc-
tion (Takasugi et al., 2011). So what is the relevance of S1P to
cancer? A major ﬁnding that addresses this question is that SK1
mRNA transcript and/or SK1 protein expression are increased
in various human tumors (Pyne and Pyne, 2010). Moreover,
S1P binds to and inhibits HDAC1/2 activity to modulate his-
tone acetylation leading to induction of immediate early genes
(Hait et al., 2009). High SK1 expression in cancer cells confers
positive selection to these cells, a consequence of a survival and
growth advantage induced by over-expression of the enzyme.
SK1 is also involved in the acquisition of replicative immortal-
ity. This is exempliﬁed by the ﬁnding that genotoxic-induced
expression of p53 in cancer cells leads to the down-regulation
of SK1 expression and the induction of death by cellular senes-
cence (Heffernan-Stroud et al., 2011). Moreover, SK1 can function
as an oncogene as evidenced by the ﬁnding that over-expression
of SK1 in ﬁbroblasts induces their transformation to ﬁbrosar-
coma (Xia et al., 2000). Whereas knockdown of SK1 reduces
proliferation of, for example, glioblastoma cells (Van Brocklyn
et al., 2005) and androgen-independent PC-3 prostate cancer cells
(Akao et al., 2006), larger, more vascularized, resistant tumors
are formed when cancer cells over-expressing SK1 are injected
or implanted into mice (Pyne and Pyne, 2010). In addition, SK1
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is a cellular “sensor” and confers chemotherapeutic resistance as it
can promote the survival of cancer cells in the presence of anti-
cancer agents (Loveridge et al., 2010). Therefore, targeting SK1
offers new approaches to the development of novel anti-cancer
therapies.
There is also evidence for a role in cancer of S1P lyase (SPL), the
enzyme that catalyses cleavage of S1P into hexadecenal and phos-
phoethanolamine. For example, the level of SPL mRNAexpression
is reduced in intestinal metastatic tumors (Oskouian et al., 2006)
and the sensitivity of lung cancer cells to cisplatin and doxorubicin
is increased by over-expression of SPL (Min et al., 2005). In addi-
tion, SPL is down-regulated in colon cancer, while over-expression
of the enzyme induces apoptosis in HEK 293 cells (Oskouian et al.,
2006). The early diagnosis of cancer is a key medical need that
enhances the chances of successful treatment. In this regard, SPL is
down-regulated in benign adenoma lesions of theApcMin/+ mouse
model, with a concomitant increase in sphingosine levels, which
induces cell death (Oskouian and Saba, 2007). Cancer progression
and full transformation to malignant tumors might arise from a
selective pressure to increase SK1 expression to remove sphingo-
sine and thereby promote adenoma cell survival, which might also
promote neoplastic conversion. This is an example where early
detection of increased expression of SK1 in the benign tumor
might warrant early chemotherapeutic intervention. This seems
to be borne out as knockout of the SK1 gene in a mouse model
of multiple intestinal adenoma (ApcMin/+) reduces intestinal ade-
noma size (Kohno et al., 2006). In addition, adenomas exhibit
higher levels of SK1 compared with normal mucosa and colon
cancer cells that have undergone metastasis have higher expres-
sion of SK1 compared with tumors without metastasis. SK1 levels
are also elevated in the azoxymethane (AOM) murine model of
colon cancer. In addition, S1P levels in the blood were higher in
mice with colon cancers than in those without cancers (Kawamori
et al., 2009).
There is also a substantial body of evidence to demonstrate a
role for S1P receptors in cancer progression. For instance, S1P
stimulates migration of ﬁbrosarcoma cells through S1P1 (Fisher
et al., 2006) and of gastric cancer cells through S1P3 (Yamashita
et al., 2006). Therefore, targeting SK1 and S1P receptors is an
attractive approach to producing new preclinical candidates for
the treatment of cancer.
SPHINGOSINE 1-PHOSPHATE AS A BIOMARKER FOR
CANCER DETECTION
Recent studies have demonstrated that the circulating levels of S1P
might serve as a biomarker for cancer progression. Pchejetski and
colleagues have reported that circulating S1P levels are consider-
ably lower in patients with prostate cancer compared with healthy
patients and that this represents an early marker for progression
to androgen-independence (Nunes et al., 2012). S1P levels also
correlated with prostate-speciﬁc antigen and lymph node status.
These authors also suggested that the decrease in circulating S1P
during prostate cancer progressionmight be related to the prostate
cancer-speciﬁc down-regulation of SK1 in erythrocytes and which
might also account for the mechanism of cancer-induced ane-
mia. Anemia closely follows the progression of prostate cancer.
A major source for blood borne S1P is the erythrocyte and
therefore circulating S1P levels are likely reduced as anemia devel-
ops and this would provide an alternative explanation of the
ﬁndings.
SPHINGOSINE KINASE 1 AS A BIOMARKER
IN ER+ BREAST CANCER
The high tumor expression of SK1 is associated with the poor
prognosis of patients with Grade 4 astrocytoma (Van Brocklyn
et al., 2005). Similarly, we have reported that high tumor expres-
sion of cytoplasmic SK1 correlates with shorter disease-speciﬁc
survival and recurrence time in estrogen receptor-positive (ER+)
breast cancer patients (Long et al., 2010; Watson et al., 2010). The
average survival time of these patients is reduced from 18 to 7.5
years and the time to recurrence of the disease in patients receiv-
ing tamoxifen is shortened by 8 years (Long et al., 2010). However,
the oncogenic background of these patients inﬂuences the clinical
outcome. Indeed, when patients were stratiﬁed according to their
HER1–3 status, high cytoplasmic SK1 expression in the tumors
was associatedwith longer disease-speciﬁc survival and recurrence
times (Long et al., 2010). Thus, SK1 is protective in this HER1–3
positive cancer phenotype, thereby underscoring the need to assess
the effect of SK1 on clinical outcome against a variety of other dis-
ease markers as some of these can alter the signaling functionality
of SK1. In this regard, we have demonstrated that SK1 is involved
in promoting the survival and migration of MCF-7 ER+ breast
cancer cells (Long et al., 2010). However, stable enforced over-
expression of HER2 increases SK1 mRNA and protein expression
and activity in these cells and results in a decrease in the expression
of HER2 in a negative feedback manner. This ablates both HER2
and S1P signaling linked with the migration of these cells (Long
et al., 2010).
The sub-cellular localization of SK1 is also an important fac-
tor affecting clinical prognostic outcome. In this regard, the
translocation of SK1 to the plasma membrane has been shown
to be a critical determinant in neoplastic transformation (Pit-
son et al., 2005). However, our ﬁndings identify an additional
novel role for the nuclear localization of SK1, which signiﬁ-
cantly shortens disease-speciﬁc survival and/or recurrence times
in ER+ breast cancer patients (Ohotski et al., 2012a). Moreover,
combinations of SK1 with other signaling proteins in the same
tumor have a profound effect on clinical outcome. The analysis
of these associations provides evidence for potentially new S1P-
dependent signaling networks in cancer cells that can be exploited
therapeutically. Thus, clinical prognostic outcome is linked with
the combined high expression of nuclear SK1 and cytoplasmic
phosphorylated c-RAF-1 or cytoplasmic phosphorylated AKT or
nuclear ERK-1/2 expression or cytoplasmic Y416 phosphorylated
SFK or LYN in the same tumor (Ohotski et al., 2012a). Some
of these functional associations represent well-deﬁned interac-
tions; for instance, SK1 has been shown to regulate AKT and
this is linked with enhanced cell proliferation and the induc-
tion of chemotherapeutic resistance in various tumors (Pyne
and Pyne, 2010). SK1 expression is also higher in ER nega-
tive (ER−) tumors compared with ER+ breast tumors and this
correlates with a poorer prognosis (Ruckhäberle et al., 2008), sug-
gesting that expression levels of SK1 are associated with disease
progression.
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S1P RECEPTORS AND CLINICAL PROGNOSIS
IN ER+ BREAST CANCER
S1P1 RECEPTOR
The high expression of both plasma membrane S1P1 receptor
and cytoplasmic Y216 phosphorylated c-SRC or phosphorylated
c-RAF-1 in the same tumor from ER+ breast cancer patients is
associated with shorter recurrence time (Ohotski et al., 2012a).
In addition, the high expression of both cytoplasmic S1P1 and
ERK-1/2 or phosphorylated AKT in the same tumor is associated
with shorter disease-speciﬁc survival time (Ohotski et al., 2012a).
These ﬁndings suggest that the S1P1/AKT and S1P1/ERK-1/2
modules might represent spatially restricted signaling pathways
in ER+ breast cancer patients that confer poor clinical prognosis
by protecting cancer cells from apoptosis and/or promoting their
growth/invasion.
S1P2 RECEPTOR
In contrast with S1P1, high tumor nuclear expression of both
c-SRC and S1P2 is associated with longer disease-speciﬁc survival
time (Ohotski et al., 2012a). In addition, tumorswith high levels of
nuclear S1P2 receptor have signiﬁcantly reduced levels of nuclear
SK1, suggesting an active translocation mechanism for SK1 that is
regulated by S1P2 and accounting for its protective action in cancer
patients. The S1P2 receptor contains a putative nuclear localization
sequence that would facilitate translocation to the nucleus and
where it might function to regulate nuclear signaling linked with
gene expression programs. Indeed, there are a number of reports
demonstrating intra-nuclear signalingbyGPCR,not least theLPA1
receptor that binds LPA (Waters et al., 2006).
S1P3 RECEPTOR
High expression of both cytoplasmic LYN and cytoplasmic S1P3
or nuclear phosphorylated c-RAF-1 and nuclear S1P3 in the same
tumor is associated with shorter disease-speciﬁc survival time
(Ohotski et al., 2012a). In addition, high expression of both
nuclear S1P3 and nuclear SK1 or cytoplasmic LYN and cytoplas-
mic S1P3 in the same tumor is associated with shorter recurrence
time (Ohotski et al., 2012a). These represent entirely novel clini-
cal and biochemical associations, which might constitute unique
biomarker signatures to predict prognostic outcome in ER+ breast
cancer patients.
S1P RECEPTORS AND CLINICAL PROGNOSIS
IN ER− BREAST CANCER
We have also reported that high tumor cytoplasmic S1P4 expres-
sion is associated with shortened disease-speciﬁc survival and
recurrence times in patients with ER− tumors (Ohotski et al.,
2012b). We report here for the ﬁrst time the stratiﬁcation of these
FIGURE 1 | Kaplan–Meier plots showing the effect of high cytoplasmic S1P4 expression on (A) disease-specific survival; (B) recurrence in ER, PgR,
HER2 negative breast cancer patients. (C) Box plot showing the correlation between node status and cytoplasmic S1P4 expression.
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data herein to consider only patients with ER, PgR, and HER2 neg-
ative breast cancer. This analysis demonstrates that high tumor
cytoplasmic S1P4 expression is also associated with shortened
disease-speciﬁc survival and recurrence times (Figures 1A,B).
High cytoplasmic S1P4 expression is also correlated with node
positive status (Figure 1C), suggesting a role for this receptor in
metastasis. Mean disease-speciﬁc survival time for patients with
tumors expressing high levels of S1P4 was 7.3 years (n = 16, IQR
4.4–10.2) compared with 11.7 years (n = 82, IQR 10.5–12.8) for
the patients with tumors expressing low levels of S1P4 (p = 0.005).
Mean recurrence time for patients with tumors expressing high
levels of S1P4 was 5.1 years (n = 14, IQR 3.2–7.0) compared
with 6.6 years (n = 78, IQR 6.0–7.2) for the patients with tumors
expressing low levels of S1P4 (p = 0.026). These new ﬁndings
identify S1P4 as an important biomarker for prognostic outcome
in triple negative breast cancer, and provide rationale for targeting
this receptor with new chemotherapeutic anti-cancer agents.
SK2 AND CANCER
There is also new emerging evidence for an important role of SK2
in cancer. This is exempliﬁed by the ﬁnding that siRNA knock-
down of SK2 in A498, Caki-1, or MDA-MB-231 cells reduces
cell proliferation and migration/invasion and this is actually more
effective than knockdown of SK1 (Gao and Smith, 2011). The
knockdown of SK1 or SK2 also have differential effects on p53,
p21, ERK1, ERK2, FAK, and VCAM1 indicating that SK1 and SK2
have non-overlapping functions. However, to date, there have been
no studies assessing the association of SK2 expression with clinical
prognosis of cancer patients.
MONITORING BIOMARKERS AS EVIDENCE-BASED
THERAPEUTICS
The major therapeutic intervention of S1P signaling in cancer
focuses on: (i) inhibition of SK1 activity; (ii) antagonism of S1P1/3
receptors; and (iii) reduction in S1P bioavailability. Clearly, it will
be important to use reliable biomarkers that provide information
regarding the effectiveness of these interventions. Toward this end,
we have reported that SK1 inhibitors [e.g., 2-(p-hydroxyanilino)-
4-(p-chlorophenyl)thiazole, N,N-dimethylsphingosine, and
FTY720] uniquely activate the ubiquitin-proteasomal degrada-
tion pathway to remove SK1 from breast and prostate cancer cells
(Loveridge et al., 2010; Tonelli et al., 2010; Ohotski et al., 2012b)
This remarkable property of SK1 inhibitors, which requires an
initial inhibition of SK1 activity to activate the proteasome,
indicates that it is possible to create cancer cells that are SK1
null, thereby eliminating its “oncogenic” effect. The “chemi-
cal knockdown” of SK1 reduces intracellular S1P and elevates
ceramide levels, which induces apoptosis (Loveridge et al., 2010).
Therefore, the “chemical knockdown” of SK1 is linked speciﬁ-
cally with apoptosis, and may represent an important reporter
for biochemical effectiveness of SK1 inhibitors in patients. The
knockdown of SK1 in the tumor can be measured in biopsy
samples, but monitoring in erythrocytes would be a signiﬁcant
advantage, although these measurements have not currently been
performed.
In addition to the above, the S1P/ceramide ratio in tumors is
also a biomarker for effective chemotherapeutic intervention. For
instance, siRNA knockdown of SK1 expression increases the sen-
sitivity of resistant leukemic cells to imatinib (Marfe et al., 2011)
and enforced expression of SK1 increases the S1P/ceramide ratio
and prevents apoptosis to imatinib (Baran et al., 2009). In addi-
tion, the S1P/ceramide ratio is reduced in response to imatinib
in imatinib-sensitive LAMA84 cells, while the ratio is unaltered
in imatinib-resistant cells. Finally, daunorubicin-sensitive but not
insensitive leukemia cells (CML,AML, andALL) exhibit a reduced
S1P/ceramide ratio when treated with daunorubicin and sensi-
tivity to daunorubicin in the latter is restored by inhibiting SK1
activity (Sobue et al., 2008).
Our ability to measure the clinical effectiveness of S1P receptor
modifying compounds in patients by monitoring effects directly
on the S1P receptor would be amajor advantage. In this regard, the
cytoplasmic S1P receptor might represent a surrogate marker for
receptor activation. This is based on the knowledge that S1P recep-
tor internalization is recognized as part of the process required for
signal transmission regulating gene re-programing of cancer cells.
Therefore, the effectiveness of S1P receptor antagonists might be
linked with reduced cytoplasmic S1P receptor levels in the tumors
of patients treated with these compounds.
CONCLUSION
Clearly, the objective of S1P therapeutics is to eliminate the nega-
tive prognostic effect of S1P receptors and SK1 on disease-speciﬁc
survival and recurrence in cancer patients. In addition to the
expression level of these biomarkers, their activity status is also
an important consideration. For instance, SK1 is activated by an
ERK-1/2-speciﬁc phosphorylation of S225 in SK1 (Pitson et al.,
2005). Future studies can utilize speciﬁc anti-phospho S225 SK1
antibody to determine the impact of phosphorylated SK1 on clin-
ical prognostic signiﬁcance. Moreover, speciﬁc assays that detect
direct functional interaction between for instance, SK1 and an
adaptor/regulatory protein using BRET and FRET technologies
would enable measurement of the activation status of speciﬁc S1P-
dependent signaling networks and these could then be correlated
with clinical prognosis.
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